Dr. Sridhar Ramaswamy is an entrepreneur in residence at GV. His focus is on building next-generation oncology companies that will transform cancer medicine.
Most recently, Dr. Ramaswamy was Senior Vice President and Head, Research & Early Development at TESARO. His team contributed to the discovery, development, regulatory approval, and / or global commercialization of 11 cancer drugs, including niraparib (PARP1/2) for ovarian and other solid tumors and dostarlimab (PD1) for uterine and other solid tumors. He was a member of the executive leadership team governing research, development, commercial, and corporate activities that spearheaded TESARO’s successful acquisition and integration by GlaxoSmithKlein for $5.1B in 2019.
Before TESARO, Dr. Ramaswamy was Associate Professor of Medicine, Tucker Gosnell Investigator, Samana Cay Scholar, and Director, Center for Cancer Systems at the MGH, Harvard Medical School, Broad Institute, Harvard Stem Cell Institute, and Harvard-Ludwig Center. Dr. Ramaswamy practiced medical oncology and hematology for twenty years at the Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute where he specialized in caring for patients with breast cancer, GI cancers, and leukemias. His NIH-funded basic and translational research program pioneered the identification of molecular mechanisms underlying cancer growth and metastasis, drug resistance, and dormancy.
After serving as Chief Resident in Medicine at Columbia-Presbyterian Medical Center, Dr. Ramaswamy completed clinical fellowships in Medical Oncology & Hematology at the Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Massachusetts General Hospital in Boston. He also completed advanced research fellowships in Cancer Biology, Immunology, and Computational Biology at the National Institutes of Health, Dana-Farber Cancer Institute / Harvard Medical School, and Whitehead Institute / MIT Center for Genome Research.
Dr. Ramaswamy is a Fellow of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the American Society for Clinical Investigation.